{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(3)"],"submitter":["Klug JH"],"pubmed_abstract":["<h4>Background & aims</h4>Immune checkpoint inhibitor (ICI) therapy has significantly improved the treatment of solid tumors such as hepatocellular carcinoma (HCC); however, most patients fail to respond. Here, we examined whether co-administration of the tumor-penetrating internalizing (i)RGD peptide, which selectively increases tumor vascular permeability in a neuropilin-1-dependent manner, enhances intratumoral delivery and therapeutic efficacy of αPD-L1 in mouse models of HCC.<h4>Methods</h4>αPD-L1, with or without iRGD, was administered intravenously to mice bearing endogenous HCCs (TGFα/c-myc and diethylnitrosamine [DEN]/carbon tetrachloride [CCl<sub>4</sub>] models). Tumor growth was monitored by MRI. Immune cell composition and activation were analyzed by flow cytometry. RNA sequen"],"journal":["JHEP reports : innovation in hepatology"],"pagination":["101731"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12907498"],"repository":["biostudies-literature"],"pubmed_title":["Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma."],"pmcid":["PMC12907498"],"pubmed_authors":["Meindl-Beinker NM","Finkelmeier F","Vogl TJ","Zeuzem S","De La Torre C","Denk D","Waidmann O","Aliraj B","Weigert A","Klug JH","Germann L","Brune B","Alcober-Boquet L","Piiper A"],"additional_accession":[]},"is_claimable":false,"name":"Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma.","description":"<h4>Background & aims</h4>Immune checkpoint inhibitor (ICI) therapy has significantly improved the treatment of solid tumors such as hepatocellular carcinoma (HCC); however, most patients fail to respond. Here, we examined whether co-administration of the tumor-penetrating internalizing (i)RGD peptide, which selectively increases tumor vascular permeability in a neuropilin-1-dependent manner, enhances intratumoral delivery and therapeutic efficacy of αPD-L1 in mouse models of HCC.<h4>Methods</h4>αPD-L1, with or without iRGD, was administered intravenously to mice bearing endogenous HCCs (TGFα/c-myc and diethylnitrosamine [DEN]/carbon tetrachloride [CCl<sub>4</sub>] models). Tumor growth was monitored by MRI. Immune cell composition and activation were analyzed by flow cytometry. RNA sequen","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Mar","modification":"2026-07-16T05:04:36.35Z","creation":"2026-07-09T10:37:28.144Z"},"accession":"S-EPMC12907498","cross_references":{"pubmed":["41704422"],"doi":["10.1016/j.jhepr.2026.101731"]}}